Truist Lowers Centene Price Target to $35, Maintains Buy Rating After Q2 Results
Truist lowers Centene price target to $35 from $42 following Q2 results, citing ongoing cost trend challenges but strong Prescription Drug Plan and Medicare Advantage performance. Buy rating maintained.